| Charles Arbie Garretson, MD | |
|
9792 Live Oak Blvd Ste E, Live Oak, CA 95953-2381 | |
| (304) 610-7267 | |
| (530) 898-1204 |
| Full Name | Charles Arbie Garretson |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 37 Years |
| Location | 9792 Live Oak Blvd Ste E, Live Oak, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144284373 | NPI | - | NPPES |
| G86610 | Other | CA | STATE LICENSE |
| GR0014101 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | G86610 (California) | Secondary |
| 207R00000X | Internal Medicine | G86610 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Butte Home Health Hospice | Chico, CA | Hospice |
| Sutter North Hospice | Yuba city, CA | Hospice |
| Oroville Hospital | Oroville, CA | Hospital |
| Enloe Medical Center | Chico, CA | Hospital |
| Orchard Hospital | Gridley, CA | Hospital |
| Windsor Chico Creek Care And Rehab Center | Chico, CA | Nursing home |
| California Park Rehabilitation Hospital | Chico, CA | Nursing home |
| Arbor Post Acute | Chico, CA | Nursing home |
| Shadowbrook Post Acute | Oroville, CA | Nursing home |
| Riverside Convalescent Hospital | Chico, CA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mundh Np And Garretson Md Medical Corporation | 6406245323 | 4 |
News Archive
Ten percent of Americans experience a seizure in their lifetime, with three million diagnosed with epilepsy, a chronic neurological disorder. Anticonvulsant medications can mitigate the hyperactivity of neurons that leads to seizures, but not without severe side effects, including cognitive impairment.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
A major step in commercializing the groundbreaking research of Dr. Doris Taylor was achieved recently when the University of Minnesota signed an exclusive, global license agreement with Miromatrix Medical Inc. Dr. Taylor's research garnered worldwide attention in 2008 when her team announced that it had created a beating animal heart in her laboratory.
Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.
› Verified 8 days ago
| Entity Name | Careconnectmd Ca Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366063125 PECOS PAC ID: 5496178055 Enrollment ID: O20200715000596 |
News Archive
Ten percent of Americans experience a seizure in their lifetime, with three million diagnosed with epilepsy, a chronic neurological disorder. Anticonvulsant medications can mitigate the hyperactivity of neurons that leads to seizures, but not without severe side effects, including cognitive impairment.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
A major step in commercializing the groundbreaking research of Dr. Doris Taylor was achieved recently when the University of Minnesota signed an exclusive, global license agreement with Miromatrix Medical Inc. Dr. Taylor's research garnered worldwide attention in 2008 when her team announced that it had created a beating animal heart in her laboratory.
Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.
› Verified 8 days ago
| Entity Name | Mundh Np & Garretson Md Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013596683 PECOS PAC ID: 6406245323 Enrollment ID: O20211116000526 |
News Archive
Ten percent of Americans experience a seizure in their lifetime, with three million diagnosed with epilepsy, a chronic neurological disorder. Anticonvulsant medications can mitigate the hyperactivity of neurons that leads to seizures, but not without severe side effects, including cognitive impairment.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
A major step in commercializing the groundbreaking research of Dr. Doris Taylor was achieved recently when the University of Minnesota signed an exclusive, global license agreement with Miromatrix Medical Inc. Dr. Taylor's research garnered worldwide attention in 2008 when her team announced that it had created a beating animal heart in her laboratory.
Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Arbie Garretson, MD 1900 Oro Dam Blvd E Ste 12, Oroville, CA 95966-5934 Ph: (304) 610-7267 | Charles Arbie Garretson, MD 9792 Live Oak Blvd Ste E, Live Oak, CA 95953-2381 Ph: (304) 610-7267 |
News Archive
Ten percent of Americans experience a seizure in their lifetime, with three million diagnosed with epilepsy, a chronic neurological disorder. Anticonvulsant medications can mitigate the hyperactivity of neurons that leads to seizures, but not without severe side effects, including cognitive impairment.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
A major step in commercializing the groundbreaking research of Dr. Doris Taylor was achieved recently when the University of Minnesota signed an exclusive, global license agreement with Miromatrix Medical Inc. Dr. Taylor's research garnered worldwide attention in 2008 when her team announced that it had created a beating animal heart in her laboratory.
Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.
› Verified 8 days ago